Akebia Therapeutics

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on developing and commercializing therapies for people living with kidney disease. With a deep understanding of the renal community, Akebia has emerged as a leader in this field. They are committed to challenging the status quo and driving innovation to improve the lives of patients.

Akebia has two FDA-approved products, VAFSEO® (vadadustat) for the treatment of anemia due to chronic kidney disease (CKD) and AURYXIA® (ferric citrate) for the control of serum phosphorus in adult patients with CKD on dialysis. They are also actively involved in research and development, with a particular focus on oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) for the treatment of anemia. Akebia collaborates with partners globally, working together to pioneer and grow new areas of research and development.

Akebia Therapeutics offers a comprehensive benefits package to support employees and their families, including flexible paid time off. This benefit allows employees to manage their work schedules and personal responsibilities, providing a degree of flexibility in their work arrangements.

Akebia Therapeutics offers a comprehensive benefits package to its employees, including health, dental, and vision insurance, a 401(k) plan with company match, stock options, flexible paid time off, an employee assistance program, commuter benefits, short- and long-term disability, and life insurance. These benefits are designed to support employees and their families, providing them with the resources they need to live healthy and fulfilling lives.

Akebia Therapeutics is a fully integrated biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that improve the lives of people living with kidney disease. They are a trusted leader in the renal community with a focus on addressing complications of kidney disease, particularly anemia, which affects millions of Americans. Akebia has a commercially available medicine and a late-stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, which is approved for use in 34 countries and is now approved by the U.S. Food & Drug Administration.

Akebia Therapeutics promotes a culture that is bold, optimistic, and collaborative. They value innovation, tenacity, transparency, connection, collaboration, integrity, and commitment. They believe in working together both within the company and with external partners to make a meaningful difference in the lives of people with kidney disease. They are committed to building a better future and creating an inclusive environment where all employees feel valued and supported.

Akebia Therapeutics is committed to building an inclusive workplace that values diversity and equity. They strive to create a culture where everyone feels valued, respected, and empowered to contribute their unique talents. Akebia believes that a diverse workforce enhances innovation and creativity, and they are committed to attracting, retaining, and developing talent from all backgrounds. They offer a comprehensive benefits package to support their employees and their families, and they are an equal opportunity employer, ensuring that qualified applicants receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or protected veteran status.